SCHEMBL13613898

SCHEMBL13613898

CC(C)OC(=O)c1ccc(-c2ccc(CC(=O)O)cc2)cc1CN(C)C1CC1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RXRA P19793 9/20 0.43
RXRB P28702 8/20 0.43
RXRG P48443 8/20 0.43
HRH3 Q9Y5N1 2/20 0.38
HRH4 Q9H3N8 1/20 0.38
NR1H4 Q96RI1 1/20 0.37
ABCC4 O15439 1/20 0.36
LMNA P02545 1/20 0.36
GAA P10253 1/20 0.36
TSHR P16473 1/20 0.36
PTGS1 P23219 1/20 0.36
HTT P42858 1/20 0.36
PTPN1 P18031 1/20 0.36
PTPN6 P29350 1/20 0.36
PTPN11 Q06124 1/20 0.36
ENPP2 Q13822 1/20 0.36
NR1H2 P55055 1/20 0.35
NR1H3 Q13133 1/20 0.35
PDCD1 Q15116 1/20 0.35
CD274 Q9NZQ7 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13986010 0.90 HRH3 (0.40) HRH3HRH4PDCD1CD274CA12
SCHEMBL13613899 0.87 NR1H4 (0.36) RXRARXRBRXRGNR1H4CA12
SCHEMBL4527243 0.87 FFAR1 (0.40) RXRARXRBRXRGCA12CA1
SCHEMBL13986027 0.86 FASN (0.39) HRH3HRH4LMNAPDCD1CD274
SCHEMBL13613881 0.85 PTGS2 (0.43) PTGS1PDCD1CD274CA12CA1
SCHEMBL14524808 0.83 PDCD1 (0.39) RXRARXRBHRH3HRH4PDCD1
SCHEMBL13986012 0.81 HTR2A (0.37) CA12CA1CA2CA7CA9
SCHEMBL4513926 0.78 NOS3 (0.44) LMNATSHRHTTCA12CA1
SCHEMBL4518329 0.77 ACACB (0.37) GAA
SCHEMBL4520102 0.76 FFAR1 (0.37) NR1H4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7638648-B2 Compounds having selective cytochrome P450RAI-1 or selective cytochrome P450RAI-2 inhibitory activity and methods of obtaining the same ALLERGAN INC. (US) 2009-12-29 US disclosed
US-7468391-B2 Methods for treating retinoid responsive disorders using selective inhibitors of CYP26A and CYP26B ALLERGAN, INC. (US) 2008-12-23 US disclosed
US-20080004455-A1 Compounds having selective cytochrome P450RAI-1 or selective cytochrome P450RAI-2 inhibitory activity and methods of obtaining the same ALLERGAN, INC. (US) 2008-01-03 US disclosed
US-7226951-B2 Compounds having selective cytochrome P450RAI-1 or selective cytochrome P450RAI-2 inhibitory activity and methods of obtaining the same ALLERGAN, INC. (US) 2007-06-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080004455-A1 Compounds having selective cytochrome P450RAI-1 or selective cytochrome P450RAI-2 inhibitory activity and methods of obtaining the same CYP1A2, CYP2A7, CYP3A7 RXRA 351/4885RXRB 407/4885RXRG 335/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.